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Summary Metallothioneins are ubiquitous low molecular weight proteins characterised by high cysteine
content and affinity for binding heavy metals. Abnormal metallothionein function and expression have been
implicated in various disease states, including neoplasia. The aim of this study was to investigate metall-
othionein expression in human breast carcinoma. Sections of routinely fixed and processed blocks of tumour
from 100 consecutive cases of primary operable breast carcinoma were stained for metallothionein using a
recently developed monoclonal antibody and a standard immunohistochemical technique. Expression was
scored on the basis of microscopical assessment ofpercentage of tumour cells staining. One patient was lost to
follow-up and excluded from the study. A significant association (P<0.0001) was observed between metall-
othionein expression and tumour type, with low levels being observed in tumours of good prognostic type.
There was also a significant association with local recurrence (P<0.02) and a significant difference (P<0.02)
in both survival and disease-free interval between tumours showing low and high levels of expression, the
latter indicating a poor prognosis. No relationship was observed with patient age, tumour size, lymph node
stage, histological grade, vascular invasion, menopausal status or oestrogen receptor status. The assessment of
metallothionein expression in human breast cancer appears to prdvide prognostic information and may have
important implications for understanding its development.
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Metallothioneins are ubiquitous low molecular weight pro-
teins characterised by high cysteine content, paucity of
aromatic amino acids and selective binding of heavy metals
such as zinc, copper and cadmium. They are present in all
vertebrates studied and are grouped into two classes, MT I
and MT II, solely on the basis of their chromatographic
behaviour. Their synthesis has been shown to be induced by
several agents, most consistently by metals but also, impor-
tantly, by stress conditions such as starvation, cold and
strenuous exercise, this being related to hormonal control at
the cellular level by glucocorticoids and interferon, regulation
ocurring at the level of transcription initiation. (For review
see Hamer, 1986).
Since their discovery (Margoshes and Vallee, 1957) and
characterisation (Kagi and Vallee, 1960) the function of
metallothioneins has been debated. There is evidence for a
role in detoxification and they are also believed to be
involved in copper and zinc metabolism (Webbs and Cain
1982). However, cell lines which fail to synthesise metall-
othionein are fully viable with a normal cell doubling time
(Comper and Palmiter, 1981), arguing against an essential
role for the intracellular activation of metalloenzymes
involved in cell division.
Recently, metallothionein has been found to be elevated in
neoplastic cells (Murphy et al., 1991) and overexpression has
been found to confer resistance to radiotherapy (Thornally
and Vasak 1985; Renan and Dowman, 1989) and chemo-
therapeutic agent toxicity (Andrews et al.,1987; Kelley et al.,
1988; Webber et al., 1988; Kaina et al., 1990), although this
has been disputed (Schilder et al., 1990; Murphy et al., 1991).
Metallothionein overexpression has been described in
human breast carcinoma and appears to be associated with a
poorer prognosis (Fresno et al., 1993; Schmid et al., 1993).
The aim of this study was to investigate further metall-
othionein expression in human breast carcinoma using an
immunohistochemical technique with a mouse monoclonal
metallothionein antibody reactive against a conserved epitope
shared by the I and II isoforms of human, rat and horse
metallothionein (Jasani and Elmes, 1991). A preliminary
study had shown high levels of metallothionein expression in
41 of 60 invasive carcinomas of no special type, but negative
or weak expression in all 26 invasive lobular carcinomas
studied (Schmid et al., 1993). We wished to investigate fur-
ther any relationship between metallothionein expression and
both prognosis and tumour type.
Materials and methods
Resected tumour specimens were obtained from 100 con-
secutive cases of primary operable breast carcinoma present-
ing symptomatically to one surgical team between 1977 and
1979. The patients were all under 70 years old with operable
tumours, UICC stage I or II. Operable tumours were defined
as those less than 5 cm in maximum extension, excluding
those which were fixed to deep tissues. They were treated by
either wide local excision or simple mastectomy with or
without radiotherapy, but received no systemic adjuvant
therapy. Lymph node stage was assessed by triple node
sampling. Patients were followed up at 3 monthly intervals
for 2 years then 6 monthly to 5 years and yearly thereafter.
The minimum length of follow-up in this series was 12 years.
The tumour specimens were received fresh, sliced into,
measured and immediately placed in 10% buffered formalin
for fixation (approximately 24 h). Blocks of tumour were
routinely processed into paraffin and sections cut for histo-
pathological assessment of tumour type, grade and vascular
invasion. Histological typing was based on the WHO
classification but with recognition of more recent types (Page
and Anderson, 1987; Ellis et al., 1992) as recommended by
the Royal College of Pathologists Working Group (1991).
We then placed the tumours into four prognostic groups on
the basis of previous studies investigating the relationship
between histological type and survival (Ellis et al., 1992;
Pinder et al., 1992), as outlined in Table I. Histological
grading (Elston and Ellis, 1991) and assessment of vascular
invasion (Pinder et al., 1994) were also performed as
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Sections 3 ,um thick were also cut and used for immunohis-
tochemical staining of metallothionein according to a stand-
ard ABC method. Briefly, the sections were dewaxed in
xylene and taken to alcohol. Endogenous peroxidase activity
was blocked with 0.5% hydrogen peroxide in methanol and
the sections washed well in running tap water and rinsed in
Tris-buffered saline (TBS). Non-specific binding sites were
blocked by applying one-fifth normal swine serum in TBS
(NSS/TBS) and excess NSS drained before applying the
primary antibody, MT E9, used in its unfractionated ascites
fluid preparation form (Jasani and Elmes, 1991; Schmid et
al., 1993) at a dilution of 1:10 000 in NSS/TBS for
30-60 min. After washing in TBS, biotinylated secondary
antibody was applied, the sections washed again and
preformed avidin-biotin complex applied. After further
washing, the label was developed using DAB solution and
the sections subsequently counterstained in haematoxylin.
Negative controls were obtained by omitting the primary
antibody and positive controls by including a known positive
with each run.
Metallothionein expression was scored by microscopic assess-
ment of the percentage of tumour cells staining and the
tumours assigned to one of four groups on the basis of this
expression. This is summarised in Table II. The degree of
metallothionein expression was then compared with a
number of tumour and patient variables as listed in Table
III.
Oestrogen receptor (ER) analysis was performed on fresh
tumour samples frozen in liquid nitrogen at the Tenovus
Institute, Cardiff, using the dextran-coated charcoal method
(Nicholson et al., 1981). ER concentrations <5 fmol mg'
cytosol protein were regarded as negative.
Table I Tumour types
Prognostic group (no. ofcases) Histological type
Excellent (4) Tubular
Tubololobular
Mucinous
Cribriform
Papillary
Good (16) Tubular mixed
Alveolar lobular
Mixed NST with special type
Average (12) Classical lobular
Lobular mixed
Medullary
Atypical medullary
Poor (67) NST (ductal)
Solid lobular
Mixed NST with lobular
NST, No special type.
Table II Metallothionein expression
No. ofcases (%) Score
10 (10.1) 1 (no positively staining tumour cells)
32 (32.3) 2 (less than 5% tumour cells positive)
31 (31.3) 3 (5-50% tumour cells positive)
26 (26.3) 4 (over 50% tumour cells positive)
Metallothioneins in breast cancer
H Goulding etal 7
969
Analysis of relationships to other variables was tested by
the chi-square test with Yates' correction. Disease-free inter-
val and survival curves were calculated by Gehan's general-
ised Wilcoxon test using the SPSSX statistical computer
package (SSPS, 1986). In accordance with convention a P-
value of<0.05 was accepted as significant.
Results
Many of the tissue sections used contained normal breast
tissue in addition to the carcinoma and we were able to
confirm previous observations by other authors of con-
sistently positive metallothionein expression in myoepithelial
cells, expression in only occasional ductal epithelial cells and
the absence of expression in epithelial cells within the lobules
(Schmid et al., 1993; Bier et al., 1994) as indicated in Figure
1. In general, the staining was easy to interpret and metall-
othionein could be demonstrated in the cytoplasm, nucleus or
both in normal and malignant cells. Although several tumour
sections also contained areas of in situ carcinoma, only the
invasive component was assessed for metallothionein express-
ion. An example of a tumour showing high levels of express-
ion is shown in Figure 2.
Figure 1 Metallothionein expression in a normal lobule.
Bar = 50gm.
Figure 2 Invasive carcinoma (no special type) showing a high
level of metallothionein expression. Bar = 50 gtm.
Table III Tumour and patient variables with results of statistical analysis
Tumour variables x2 Patient variables x2
Histological grade P = 0.07 Age P = 0.85
Tumour type P<0.0001 Menopausal status P = 0.45
Lymph node stage P = 0.49 Local recurrence P<0.02
Oestrogen receptor status P = 0.89 Disease-free interval (see Figures 3 and 5)
Tumour size P = 0.48 Survival (see Figures 4 and 6)
Vascular invasion P = 0.11Metallothioneins in breast cancer 00 H Goulding etal
One patient was lost to follow-up and therefore excluded.
The remaining 99 cases showed considerable variation in the
degree of metallothionein expression in the tumour cells
(Table II). Statistical analysis revealed a significant associa-
tion between metallothionein expression and the groups of
tumour type (P<0.001), with low levels of expression being
observed in tumours of good prognostic subtypes (Table IV).
There was also a significant association between high levels
of expression and local recurrence (P<0.02, Table V).
This group of patients had an overall survival of around
90% at 2 years and 60% at 5 years, as would be expected for
a series of stage I and II tumours. Life-table analysis revealed
a tendency towards reduced disease-free interval and survival
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Figure 3 Disease-free interval relative to metallothionein expr-
ession.
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in patients whose tumours showed a high level of metall-
othionein expression (Figures 3 and 4), although this did not
reach statistical significance when the tumours were sub-
divided into four groups on the basis of the percentage of
positively staining tumour cells as outlined in Table II. How-
ever, if the tumours were divided into only two groups - low
(showing 0-50% positive cells) and high (showing>50%
positive cells), - a statistically significant difference in survival
and disease-free interval was observed (Figures 5 and 6).
There was no significant association between metall-
othionein expression and the other tumour and patient
variables examined (probability values for chi-square test
given in Table III).
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Figure 5 Disease-free interval relative to high or low metall-
othionein expression. P<0.02.
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Figure 4 Survival function relative to metallothionein express-
ion.
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Figure 6 Survival function relative to high or low metall-
othionein expression. P<0.02.
Table IV Metallothionein expression and tumour type
MT= I MT=2 MT=3 MT=4 Prognostic
(0) (<5%) (5-50%) (>50%) Group
totals
Group 1 3 1 4
Group 2 5 7 2 2 16
Group 3 2 7 3 12
Group 4 2 23 22 20 67
MT score 10 32 31 26 99
Totals
Chi-square, 38.66803; d.f., 9, P<0.0001.
Table V Metallothionein expression and local recurrence
MT= I MT=2 MT=3 MT= 4 Recurrence
(0) (<5%) (5-50%) (>50%) Totals
No local recurrence 10 24 22 13 69
Local recurrence 8 9 13 30
MT score 10 32 31 26 99
Totals
Chi-square, 9.57370, d.f., 3, P<0.02.
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Discussion
We chose to examine the expression of metallothionein in
human breast carcinoma using an immunohistochemical
technique as this has the major advantage over other
methods - either indirect (e.g. chromatographic separation)
or direct (e.g. radioimmunoassay) - of allowing localisation
of metallothionein within the tissue examined. Furthermore,
the technique, which is now well established, is possible with
routinely fixed and processed tissue, without the need for
preselection of tissue for separate analysis.
This study confirms metallothionein overexpression in
invasive breast carcinoma and further, our finding of no
significant association between metallothionein and tumour
size suggests that where overexpression does occur it does so
early in the lifetime of the tumour, possibly during carcino-
genesis. This would be consistent with previous reports of
metallothionein induction occuring during carcinogenesis
(Angel et al., 1986) and ultraviolet irradiation (Jasani et al.,
1993) and a recent observation of increased metallothionein
expression in breast epithelial hyperplasias and ductal car-
cinoma in situ (Bier et al., 1994), but does not necessarily
imply a causative role. With their affinity to bind potentially
carcinogenic metals (e.g. cadmium) (Hamer, 1986) and
metabolites (e.g. free radicals) (Thornally and Vasak, 1985)
metallothioneins do have the potential to effect the car-
cinogenic process in a way which may be either deleterious or
protective to the cell. Whatever the involvement of metall-
othionein may be in carcinogenesis and tumour progression,
in our study, with a minimum of 12 years follow-up, we have
confirmed an association between increased expression and
poor prognosis as has been described previously in studies
with shorter follow-up times (Fresno et al., 1993; Schmid et
al., 1993).
We have confirmed the variation of expression of metal-
lothionein in both normal and neoplastic breast tissues
(Fresno et al., 1993; Schmid et al., 1993; Bier et al., 1994)
with tumours of favourable prognostic subtype showing
significantly lower levels of expression than tumours of poor
prognostic subtype. Our preliminary study and those of
others (Fresno et al., 1993; Schmid et al., 1993; Bier et al.,
1994) have shown lack of expression in normal lobular
epithelium and little or no expression in lobular carcinomas.
While we do not wish to suggest that the lack of expression
in both benign lobular epithelium and lobular carcinoma
implies that lobular carcinoma arises from lobular epith-
elium, we note the observation with interest. Differences in
metallothionein expression between different tumour types is
another manifestation of their phenotypic diversity and may,
at least in part, explain the observed differences in prognosis.
Further studies with larger numbers of specimens are
required to assess the significance of metallothionein over-
expression in different tumour types.
We looked specifically for an association between metall-
othionein expression and tumour grade but, unlike Fresno et
al. (1993), we found the level ofmetallothionein expression to
be independent of the degree ofdifferentiation of the tumour.
Thus, although the good prognostic tumour types may be
expected often to be of lower grade than the poor prognostic
types, this alone cannot account for our observation of an
association between tumour type and metallothionein exp-
ression.
We found no association between metallothionein express-
ion and ER status, although such an association has been
described (Fresno et al., 1993) and it has been further sugg-
ested that metallothionein overexpression is associated with a
poor prognosis only in ER-negative tumours, the association
being lost in ER-positive tumours which would be expected
to respond to anti-oestrogen therapy (Schmid et al., 1993).
This may be of particular significance if metallothionein
overexpression is associated with resistance to chemotherapy
and radiotherapy in breast carcinoma as has been suggested
for other tumours (Andrews et al., 1987; Kelley et al., 1988;
Renan and Dowman, 1989), as it is those patients with
ER-negative tumours who are likely to be assigned to such a
therapeutic regimen rather than anti-oestrogen therapy.
Although much remains uncertain regarding the physiol-
ogical functions ofmetallothioneins and their role in carcino-
genesis and other disease processes, and although immuno-
histochemical detection does not necessarily imply functional
capability, we have found that elevated levels of expression
detected in this way are associated with poor prognostic
tumour types and with an increased likelihood of local
recurrence, shortened disease-free interval and reduced sur-
vival. This may have implications for understanding the cell-
ular origins, development and progression of human breast
cancer.
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